SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
IMMX

Immix Biopharma, Inc. (IMMX)

NASDAQ: IMMX · USD
Healthcare · Biotechnology
$7.20-$0.28 (-3.74%)
 
Market cap
$603M
Insider Score
Analyst consensus
Market Cap$603.45M+78.2%
Revenue (ttm)n/a
Net Income-$46.26M
EPS-$0.83
Shares Out83.81M
PE Ration/a
Forward PE-7.12
Dividendn/a
Ex-Dividend Daten/a
Volume993,758
Open$7.48
Previous Close$7.48
Day's Range$7.12 - $7.52
52-Week Range$3.78 - $15.10
Beta0.29
AnalystsStrong Buy
Price Target$23.93(+232.29%)
Earnings DateNov 12, 2026

About IMMX

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Address
11400 West Olympic Boulevard, Los Angeles, CA, 90064, United States
Market Cap
603 million
Employees
21
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$20.21K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

1 Day
-3.74%
5 Days
-13.77%
1 Month
-12.41%
6 Months
-18.74%
1 Year
+78.22%

$IMMX stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in IMMX holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by IMMX's directors and management

Net Shares Purchased by Insiders−2k−1k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

IMMX Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New IMMX patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to IMMX from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from IMMX’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
No data yet
—
Analyst Ratings
62% of score
99
News & Sentiment
38% of score
72

News check: Bullish interim trial data and Q3 results offset by modest analyst price target reduction while maintaining outperform rating.

Recent Insider Activity

Buys
4
Sells
0
Buy Value
$20.21K
Distinct Buyers
2

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

BBCVirtus Biotech Clinical Trials ETF0.76%
DWASInvesco Dorsey Wright SmallCap Momentum ETF0.53%
XBIState Street SPDR S&P Biotech ETF0.17%
IWCiShares Micro-Cap ETF0.13%
OPTZOptimize Strategy Index ETF0.11%
VFMOVanguard U.S. Momentum Factor ETF0.10%
TNXTT. Rowe Price Innovation Leaders ETF0.06%
VMO.TOVanguard Global Momentum Factor ETF0.05%
VTWGVanguard Russell 2000 Growth ETF0.04%
PWSPacer WealthShield ETF0.04%
LABUDirexion Daily S&P Biotech Bull 3X Shares0.03%
IWOiShares Russell 2000 Growth ETF0.03%

Weight is the stock’s share of each fund’s holdings.